TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12665918
Drug: Common liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common liver protection drugs
Study: 9699124
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 0.1 IU/Kg i.m. for 3 days
Study: 1683503
Drug: Quinagolide 0.05
Normalized name: quinagolide 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide 0.05 mg
Study: 1683503
Drug: Quinagolide (incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide (incremental doses for 6 months)
Study: 1683503
Drug: Bromocriptine (incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (incremental doses for 6 months)
Study: 30218226
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions including the use of tongue scraper
Study: 30218226
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions alone without tongue cleaning
Study: 25784519
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg twice daily for 8 days starting 48 hours before surgery)
Study: 19137320
Drug: 0.1% ISMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% ISMN gel
Study: 19137320
Drug: 0.1% GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% GTN gel
Study: 14995003
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (IVCYC) 0.5 g/m² body surface area, monthly
Study: 14995003
Drug: Oral enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enalapril 10 mg/day
Study: 11483846
Drug: Omalizumab (0.016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (0.016 mg/kg/IgE [IU/mL] per 4 weeks)
Study: 9608348
Drug: Frequent take-home
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent take-home medication doses during baseline (8-week duration)
Study: 9608348
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg take-home doses during contingency management
Study: 9608348
Drug: Fluoxetine 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 0 mg and 20 mg take-home doses during contingency management
Study: 8107741
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a (1.5 million units thrice weekly for 1 week, then 3 million units thrice weekly for 23 weeks)
Study: 8107741
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no additional treatment apart from previously prescribed treatments)
Study: 8107741
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa-2a (resumption of treatment)
Study: 30822358
Drug: Biologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapies (ustekinumab) in RCTs
Study: 30822358
Drug: Real-world populations
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world populations on biologic therapies
Study: 26700981
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (two 200-μg tablets every 4 hours for up to 48 hours)
Study: 26700981
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (two 200-μg tablets inserted every 4 hours for 48 hours)
Study: 26700981
Drug: Combination route
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination route (two 200-μg tablets vaginally followed by 400 μg sublingually every 4 hours for 48 hours)
Study: 23389691
Drug: GABAA receptors
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABAA receptors in vmPFC and sensorimotor cortex
Study: 21848959
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of pure ethanol/kg of body weight (low dose: LD)
Study: 21848959
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of pure ethanol/kg of body weight (high dose: HD)
Study: 21848959
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of pure ethanol/kg of body weight (control)
Study: 14735686
Drug: Schedule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A (weekly)
Study: 14735686
Drug: Schedule B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B (twice weekly for 2 weeks repeated every 21 days)
Study: 14735686
Drug: Schedule C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule C (twice weekly every other week)
Study: 4025164
Drug: FDP (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDP (250 mg/kg body weight in isotonic saline solution intravenously in 20 minutes)
Study: 23721512
Drug: Cladribine-based combinations
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine-based combinations (CMC: 2-CdA, cyclophosphamide, mitoxantrone; CC: 2-CdA, cyclophosphamide)
Study: 23721512
Drug: 2-CdA monotherapy
Normalized name: 2-CdA
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-CdA monotherapy
Study: 23721512
Drug: Cladribine-based combinations
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine-based combinations (CMC, CC)
Study: 12045171
Drug: roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (300 mg daily) for 28 days
Study: 7710412
Drug: Myo device,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo device, chewed for four minutes, twice daily
Study: 7710412
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (customary oral hygiene procedures only)
Study: 2632755
Drug: Dialysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis with a 'low-calcium' dialysate (1.50 mmol/l)
Study: 2632755
Drug: Dialysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis with a 'high-calcium' dialysate (1.75 mmol/l)
Study: 27031376
Drug: Spectral CT
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectral CT with 350 mgI kg(-1) contrast injection
Study: 25910889
Drug: Laryngoscopy (L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laryngoscopy (L group)
Study: 21087825
Drug: Intravenous arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous arginine (30 g for 5 days)
Study: 21087825
Drug: Placebo (25.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25.2 g of alanine for 5 days)
Study: 18503398
Drug: Warfarin 5.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 5.75 mg once/day (uniform dosage)
Study: 18503398
Drug: Warfarin 7.5
Normalized name: warfarin 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 7.5 mg/day on Mondays and Fridays and 5 mg/day on each of the remaining days (nonuniform dosage)
Study: 10699472
Drug: Advice not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice not to wash hair during treatment (group 1)
Study: 9336364
Drug: 125 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/m2 IDEC-C2B8
Study: 9336364
Drug: 250 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/m2 IDEC-C2B8
Study: 9336364
Drug: 375 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/m2 IDEC-C2B8
Study: 8186669
Drug: Outpatient treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatments for marijuana dependence
Study: 3533670
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg, t.d.)
Study: 24531025
Drug: Macular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macular laser therapy
Study: 19404953
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone
Study: 19404953
Drug: High-dose prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisone
Study: 21033120
Drug: Systemic red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic red light therapy, once a day, 30 minutes until wounds recovered.
Study: 21033120
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy (Control group)
Study: 21033120
Drug: Systemic red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic red light therapy
Study: 7681894
Drug: Dipyridamole (PDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (PDE inhibitor)
Study: 7681894
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) patches, 10 mg/24 h
Study: 26420590
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (1 g/d)
Study: 23743397
Drug: Acetaminophen (APAP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP), 1,000 mg
Study: 21649830
Drug: Home-use hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-use hydrogen peroxide bleaching agents (PolaDay 7.5%, PolaDay 9.5%, DayWhite ACP-7.5%, DayWhite ACP 9.5%) and in-office agents (PolaOffice 35%, Opalescence XtraBoost 38%) applied for 30 minutes/day for 21 days or in one session a week for 3 weeks.
Study: 20001836
Drug: Ping On
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ping On ointment
Study: 15536462
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (300 mg three times daily)
Study: 15536462
Drug: Imipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50 mg three times daily)
Study: 11699402
Drug: Cefpirome (CPO)
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome (CPO) 2 g x 2/day
Study: 11699402
Drug: Piperacillin-tazobactam (PT)
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (PT) 4 g x 3/day
Study: 8501490
Drug: Sequential Postremission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Postremission Chemotherapy (SPC)
Study: 29450870
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (propranolol, amitriptyline, flunarizine, topiramate)
Study: 26331608
Drug: Basal or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal or poststimulated 17OHP ≥30 nmol/l (group A)
Study: 26331608
Drug: Poststimulated 17OHP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poststimulated 17OHP <30 nmol/l (group B)
Study: 25397800
Drug: 0.7-mm machined-collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7-mm machined-collar implants
Study: 25397800
Drug: 1.5-mm machined-collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5-mm machined-collar implants
Study: 20672994
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) once-daily (QD) with tenofovir DF and emtricitabine
Study: 20672994
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) twice-daily (BID) with tenofovir DF and emtricitabine
Study: 20672994
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) once-daily (QD)
Study: 20672994
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) twice-daily (BID)
Study: 30004141
Drug: Regulations limiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regulations limiting exposure to unwanted drones; specific details on dosage and duration not applicable.
Study: 30004141
Drug: Regulations hampering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regulations hampering drones used for public safety; specific details on dosage and duration not applicable.
Study: 30004141
Drug: Regulations protecting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regulations protecting personal privacy; specific details on dosage and duration not applicable.
Study: 30290902
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin at 1.8 mg/kg via intravenous infusion once every 3 weeks for up to 16 cycles (recommended phase 2 dose).
Study: 30290902
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin at 1.8 mg/kg.
Study: 22220931
Drug: Berberine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (300 mg, t.i.d., for 30 days)
Study: 17112401
Drug: TAU+OT (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU+OT (treatment as usual plus occupational therapy)
Study: 16148823
Drug: Standard-dose epinephrine
Normalized name: epinephrine Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose epinephrine
Study: 10983527
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg single dose
Study: 10983527
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg two doses on 2 consecutive days
Study: 1976576
Drug: Sulphasalazine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphasalazine treatment for four weeks
Study: 1976576
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid treatment for four weeks
Study: 1976576
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment after sulphasalazine
Study: 27855998
Drug: Teduglutide 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.05 mg/kg/d
Study: 23333663
Drug: Teduglutide 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide 0.10 mg/kg/d
Study: 23333663
Drug: Teduglutide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide (both doses)
Study: 15586183
Drug: Psycho-educative group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-educative group-based treatment programme (8 weeks, weekly sessions of 2.5 hours, booster sessions after 1, 2, and 4 months)
Study: 1849159
Drug: Topical ACV
Normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ACV (started 5 min after UVR)
Study: 6277698
Drug: Cyclic estrogen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic estrogen regimen (0.625 mg of conjugated estrogens, 3 weeks on, 1 week off)
Study: 6277698
Drug: Continuous estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous estrogen regimen (0.625 mg of conjugated estrogens, daily)
Study: 26682998
Drug: Omega-3 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 and omega-6 supplements for 12 weeks
Study: 21182509
Drug: FSL phototherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FSL phototherapy (twice per week for 4 weeks)
Study: 19947442
Drug: Sublingual nimesulide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nimesulide
Study: 17511722
Drug: PSA <
Normalized name: Prostate-Specific Antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA < 4 ng/mL with doubtful DRE finding
Study: 11437873
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (10 mL h(‐1))
Study: 11437873
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine (10 mL h(‐1))
Study: 11437873
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine with 0.5 microg mL(‐1) sufentanil (BS)
Study: 11437873
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine with 0.5 microg mL(‐1) sufentanil (RS)
Study: 11437873
Drug: 0.5 microg
Normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microg mL(‐1) sufentanil only (S)
Study: 9881243
Drug: Sulphonylurea treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphonylurea treatment
Study: 27029390
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for chronic progressive diseases (specific intervention details not available)
Study: 25545540
Drug: Esmolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (100 μg/kg per min for 10 mins, then 50 μg/kg per min for 50 mins)
Study: 25545540
Drug: Tecadenoson (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecadenoson (75 μg)
Study: 25545540
Drug: Tecadenoson (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecadenoson (300 μg)
Study: 22562973
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy (PBO+MTX)
Study: 3096035
Drug: Terbutaline (T)
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline (T) infusion
Study: 26586786
Drug: MTP-131 infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 infused at a rate of 0.05 mg/kg/h for 1 h
Study: 24145543
Drug: Ganciclovir at
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir at 5 mg/kg body weight intravenously
Study: 24145543
Drug: Ganciclovir dose
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir dose of 2.5 mg/kg once daily
Study: 22001666
Drug: Music intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music intervention (at least 2 daily sessions of music listening between D0 and D10, continued at home until D60)
Study: 18763685
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (2.5% lidocaine/2.5% prilocaine)
Study: 18763685
Drug: Oraqix thermosetting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraqix thermosetting gel (2.5% lidocaine/2.5% prilocaine)
Study: 16053244
Drug: Pharmaceutical grade
Normalized name: CVS Pharmaceutical Grade Fish Oil 1000mg Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical grade tryptophan with carbohydrate
Study: 2139413
Drug: vehicle 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle 0.9% NaCl40 ml and 20% albumin 5 ml
Study: 6992833
Drug: Ro 10-9359
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 10-9359 (100 mg daily initially, maintenance dose 50 mg)
Study: 24806030
Drug: Acarbose/metformin 50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose/metformin 50/500 mg FDC (test)
Study: 24806030
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg and metformin 500 mg as loose combination (reference)
Study: 24806030
Drug: Acarbose/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose/metformin FDC and loose combination
Study: 16344839
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 20‐60 mg/day
Study: 12170853
Drug: ITI implant
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI implant system
Study: 12170853
Drug: Steri-Oss implant
Normalized name: BANDAGE,STERI-STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steri-Oss implant system
Study: 12170853
Drug: Southern implant
Normalized name: Fluzone 2025 Southern Hemisphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern implant system
Study: 8552232
Drug: Baclofen (GABAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (GABAB receptor agonist) administered pre-operatively with morphine (mu-opioid analgesic)
Study: 8552232
Drug: Baclofen (GABAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (GABAB receptor agonist) administered with pentazocine (kappa-opioid analgesic)
Study: 8552232
Drug: Pentazocine (kappa-opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (kappa-opioid analgesic)
Study: 27552802
Drug: Educational session
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational session focusing on the importance of adherence to medication (30 minutes)
Study: 22829691
Drug: Low-dose etanercept
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etanercept (25 mg/week)
Study: 22829691
Drug: Standard-dose etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose etanercept (50 mg/week)
Study: 22829691
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Low-dose and Standard-dose etanercept)
Study: 20833514
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean dose 10.9 mg)
Study: 20833514
Drug: Ziprasidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (mean dose 88.9 mg)
Study: 20833514
Drug: Olanzapine to
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine to Ziprasidone switch (mean dose 136 mg)
Study: 20833514
Drug: Ziprasidone to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone to Olanzapine switch (mean dose 16 mg)
Study: 26427866
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with clonidine (LC; 15 mcg/ml)